SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.

Autor: Finch E; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom., Lowe R; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Barcelona Supercomputing Center (BSC), Barcelona, Spain.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain., Fischinger S; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Institut für HIV Forschung, Universität Duisburg-Essen, Duisburg, Germany., de St Aubin M; Harvard Humanitarian Initiative, Cambridge, Massachusetts, United States of America., Siddiqui SM; Computational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Dayal D; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Loesche MA; Space Exploration Technologies Corp, Hawthorne, California, United States of America.; Brigham and Women's Hospital, Boston, Massachusetts, United States of America., Rhee J; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Beger S; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Hu Y; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Gluck MJ; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Mormann B; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Hasdianda MA; Brigham and Women's Hospital, Boston, Massachusetts, United States of America., Musk ER; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Alter G; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Menon AS; Space Exploration Technologies Corp, Hawthorne, California, United States of America., Nilles EJ; Harvard Humanitarian Initiative, Cambridge, Massachusetts, United States of America.; Brigham and Women's Hospital, Boston, Massachusetts, United States of America., Kucharski AJ; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Jazyk: angličtina
Zdroj: PLoS biology [PLoS Biol] 2022 Feb 10; Vol. 20 (2), pp. e3001531. Date of Electronic Publication: 2022 Feb 10 (Print Publication: 2022).
DOI: 10.1371/journal.pbio.3001531
Abstrakt: Identifying the potential for SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,411 United States employees in 4 states between April 2020 and February 2021. We conducted a multivariable logistic regression investigating the association between baseline serological status and subsequent PCR test result in order to calculate an odds ratio for reinfection. We estimated an odds ratio for reinfection ranging from 0.14 (95% CI: 0.019 to 0.63) to 0.28 (95% CI: 0.05 to 1.1), implying that the presence of SARS-CoV-2 antibodies at baseline is associated with around 72% to 86% reduced odds of a subsequent PCR positive test based on our point estimates. This suggests that primary infection with SARS-CoV-2 provides protection against reinfection in the majority of individuals, at least over a 6-month time period. We also highlight 2 major sources of bias and uncertainty to be considered when estimating the relative risk of reinfection, confounders and the choice of baseline time point, and show how to account for both in reinfection analysis.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: GA is a founder of Seromyx Systems Inc., a company developing platform technology that describes the antibody immune response. GA’s interests were reviewed and are managed by Massachusetts General Hospital in accordance with their conflict-of-interest policies. MJG, SB, DD, YH, JR, EP, BM, ASM, and ERM are employees of Space Exploration Technologies Corp. All other authors have declared that no conflict of interest exists.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje